PATENT CLAIM ANALYSIS

Application Number: 15902643
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "023000"]

Abstract:
The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.

Claim (Index 31):
A pharmaceutical composition comprising (a) a neuroleptic agent and (b) an SGLT2 inhibitor, wherein said SGLT2 inhibitor is empagliflozin, dapagliflozin or canagliflozin and wherein said neuroleptic agent is olanzapine, haloperidol or clozapine.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.16129
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13912599', '14048880', '12673327', '12894385', '14918713']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7634506529700624
- 35 USC 102 Novelty (BERT): 0.5323004012071539
- Combined Prediction Score: 0.7403356277937716
- Mean Citation Score: 294.680162
- Max Citation Score: 363.7473
- Similarity Product: 217.42934445481896

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test